

# ➤ CYGNUS® MATRIX AMNIOTIC MEMBRANE TISSUE ALLOGRAFT

# CYGNUS® MATRIX

## CHRONIC RIGHT DIABETIC FOOT ULCER CASE STUDY

The patient is a 59-year-old male with diabetic neuropathy presenting a diabetic foot ulceration in the right plantar forefoot, which had been existent for 6 months prior to the first application of CYGNUS® Matrix amniotic membrane tissue allograft. The non-infected wound was caused by a deformity in the second metatarsal and had been treated with Iodoflex, a Cam Walker boot, and non-adhesive foam, only to remain open.

## ➤ APPLICATION OF VIVEX® BIOLOGICS CYGNUS® MATRIX AMNION TISSUE ALLOGRAFT AND OUTCOME

CYGNUS Matrix amniotic membrane tissue allografts were applied to the diabetic foot ulcer as a soft tissue barrier and wound covering, providing protection while retaining endogenous growth factors.<sup>1,2</sup> Non-adhesive foam, dry gauze dressing and Ace bandages, and ¼ felt padding were applied as a dressing. The patient was successful at keeping weekly dressings intact and thorough the 6 weeks of treatment with CYGNUS Matrix. The size of the wound prior to the first application of CYGNUS Matrix was 0.9cm L x 0.7cm W x 0.3cm D.



**AFTER 2<sup>ND</sup> APPLICATION  
OF CYGNUS MATRIX**

Wound Dimensions:  
0.8cm L x 0.6cm W x 0.3cm D



**AFTER 3<sup>RD</sup> APPLICATION  
OF CYGNUS MATRIX**

Wound Dimensions:  
0.6cm L x 0.5cm W x 0.3cm D



**AFTER 4<sup>TH</sup> APPLICATION  
OF CYGNUS MATRIX**

Wound Dimensions:  
0.2cm L x 0.4cm W x 0.1cm D



**AFTER 6<sup>TH</sup> APPLICATION  
OF CYGNUS MATRIX**

Complete Wound Closure

**After 6 CYGNUS Matrix applications over the course of 6 weeks, the patient achieved complete wound closure without drainage or dressing requirements.**

The patient had previously been treated with traditional wound care including non-adhesive foam dressing, Iodoflex, and off-loading boot along with weekly debridement. These methods did not work. Utilizing CYGNUS Matrix achieved **complete wound closure**.

## ➤ CONCLUSION

This case study demonstrates the use of VIVEX CYGNUS Matrix amniotic membrane tissue allograft as a soft tissue barrier and wound covering to help close a chronic full-thickness diabetic foot ulcer. The CYGNUS tissue allograft is easy to apply, is available in multiple sizes, and will conform to wounds.

## ► CYGNUS MATRIX

CYGNUS Matrix is a multi-layer membrane allograft maintaining the amnion layer, its intermediate/spongy layer, and the chorion layer of the amniotic sac. VIVEX's Integrity Processing™ preserves the inherent properties of amniotic tissues, maintaining key extracellular matrix molecules, proteins, carbohydrates, collagen, growth factors, and cytokines.<sup>1,2</sup>

## ► SAFE AND TRUSTED PARTNER

VIVEX Biologics focuses on patient care through the innovation of tissue-based therapies in Wound Care, Ortho-Fusion, and Interventional Pain. With more than 50 years of highly safe and effective operations, VIVEX aims to provide advanced regenerative solutions.

- Amniotic tissue is recovered from healthy mothers at live births.
- Amniotic tissue is handled and processed in accordance with both FDA regulations and AATB standards.
- VIVEX maintains the trend of safely delivering over 2 million allografts with no disease transmission.

---

This research study is designed to test a product manufactured by VIVEX. The health care professional leading this research study receives compensation from VIVEX for services related to and unrelated to this study, including consulting services. VIVEX has used reasonable efforts to provide accurate and complete information herein, but this information should not be construed as providing clinical advice, dictating reimbursement policy, or as a substitute for the judgment of a health care provider. It is the health care provider's responsibility to determine the appropriate treatment, codes, charges for services, and use of modifiers for services rendered and to submit coverage or reimbursement-related documentation.

1. Delcroix GJ, et al. Preserving the natural regenerative potential of amniotic membrane, VIVEX Biologics.  
2. Niknejad H, et al. Properties of the amniotic membrane for potential use in tissue engineering. *Eur Cell Mater* 2008;15:88-89.

